Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof

Inventors

Petersen, John S.

Assignees

SynDevRX Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9730955-B2

Patent

Publication Date

2017-08-15

Expiration Date


Abstract

One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor.

Core Innovation

The described invention relates to polymer-conjugated MetAP2 inhibitors comprising polymer carriers and fumagillin-related moieties, including HPMA copolymers bearing fumagillol or dihydrofumagillol. The conjugates incorporate peptide linkers, such as GFLG, as well as chemical, amine, amino-acid, or self-immolating linkers that release a carbamate-form inhibitor. These conjugates provide antiangiogenic activity for proposed applications including cancer, abnormal or hyperpermeable vasculature, endothelial-cell proliferation, and other angiogenic diseases.

The polymer-conjugated inhibitors address toxicity, short half-life, and formulation challenges associated with TNP-470 and related small molecules. These conjugates are intended to improve efficacy, enhance pharmacokinetic profiles, and provide activity at lower doses than parent small molecules. In addition, the independent claims cover pharmaceutical compositions comprising recited compounds or their pharmaceutically acceptable salts and a pharmaceutically acceptable carrier, with certain compositions specifying ranges for x, y, and n.

Claims Coverage

The provided claims include independent claims 1, 3, 4, 6, 7, 9, and 10, covering pharmaceutical compositions comprising recited compounds or their pharmaceutically acceptable salts and a pharmaceutically acceptable carrier, encompassing two primary inventive features.

Composition with specified x, y, and n ranges

Independent claims 1, 4, and 7 recite a pharmaceutical composition comprising the recited compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein x is between 1 and about 450, y is between 1 and about 30, and n is between 1 and about 50.

Composition comprising a recited compound

Independent claims 3, 6, 9, and 10 recite a pharmaceutical composition comprising the recited compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein the compound structure is not displayed in the provided text.

The independent claims encompass pharmaceutical compositions containing recited compounds or their pharmaceutically acceptable salts with a pharmaceutically acceptable carrier, with claims 1, 4, and 7 additionally defining ranges for x, y, and n.

Stated Advantages

The examples report reduced B16-F10 lung metastases in mice and slower tumor growth in an A549 xenograft model for treated groups compared with the stated controls.

Carbamoylfumagillol is reported to show less than 20% decomposition over seven days across the stated pH range.

The polymer-conjugated inhibitors are intended to improve efficacy and pharmacokinetic profile over parent small molecules.

The polymer conjugates demonstrate potential activity at lower doses than the corresponding small molecules.

Documented Applications

The examples describe HPMA-co-MA-GFLG polymer conjugates bearing fumagillol-derived groups in connection with antitumor activity, including assessments in B16-F10 lung metastasis and A549 xenograft models.

Proposed antiangiogenic applications, including treatment or prevention of cancer, abnormal or hyperpermeable vasculature, endothelial-cell proliferation, and other angiogenic diseases.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.